Getting latest data loading
Home / Morning Report / Morning Report – 20th December 2024

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 20 December 2024

Yesterday’s UK 100 Leaders Price (p) % Chg
Severn Trent PLC 2574 0.94%
Imperial Brands PLC 2572 0.55%
Hikma Pharmaceuticals PLC 1935 0.36%
Diageo PLC 2525.50 0.28%
Admiral Group PLC 2614 0.19%

 

Yesterday’s UK 100 Laggards Price (p) % Chg
Pershing Square Holdings LTD 3732 -3.76%
Mondi PLC 1145.50 -3.66%
Ashtead Group PLC 4990 -3.41%
Marks & Spencer Group PLC 378.20 -3.40%
British Land Company PLC 351.6 -3.35%
Major World Indices Price % Chg 1 Year
UK 100 INDEX 8,105 -1.1% 5.1%
DOW JONES INDUS. AVG 42,342 0.0% 14.2%
DAX INDEX 19,970 -1.4% 19.3%
NIKKEI 225 38,702 -0.3% 14.9%
S&P/ASX 200 INDEX 8,067 -1.2% 7.0%

 

Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 69.04 -0.49%
Brent Crude (ICE) USD/bbl. 72.54 -0.47%
Gold Spot USD/t oz. 2,606 0.5%
Copper (Comex) USd/lb. 408 0.2%
The UK 100 called to open -5 points at 8,100

4 Hours; 12 Months

Click graph to enlarge

Markets Overview:

The UK 100 called to open -5 points at 8,100. The UK 100 looks set to open marginally lower this morning following yesterdays significant fall.

The Dow Jones narrowly snapped its longest losing streak since 1974 on Thursday.  The 30-stock Dow added 15.37 points, or 0.04% to close at 42,342.24. The S&P slid 0.09% to 5,867.08, while the Nasdaq fell 0.10% to 19,372.77.

Asia-Pacific markets mostly fell on Friday as investors digest inflation data out of Japan, as well as an interest rate decision out of China.  The People’s Bank of China held its loan prime rates steady on Friday, leaving the one-year rate unchanged at 3.1% and the five-year rate at 3.6%.

Company News & Broker Comments:

Company News:

GSK today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula (niraparib) and Jemperli (dostarlimab) in first line advanced ovarian cancer. The trial met its primary endpoint of PFS demonstrating a statistically significant difference with the addition of dostarlimab to both standard of care carboplatin-paclitaxel chemotherapy and niraparib maintenance, with or without bevacizumab.

 

 

Broker Comments:

No New Broker Comments

 

 

Reporting Today:

UK

 

None

 

 

US

 

None

Reporting Tomorrow:

UK

 

None

 

US

 

None

In Focus Today:

EU leaders summit

PBoC Interest Rate Decision

German Producer Price Index

UK Retail Sales

US Personal Consumption Expenditures

EU Consumer Confidence

Michigan Consumer Sentiment Index

UoM 5-year Consumer Inflation Expectation

 

Next Week’s Ex-Dividends:

UK 100 companies going ex-dividend on 24th December 2024:

 

BT Group

UK 250 companies going ex-dividend on 24th December 2024:

 

Schroder AsiaPacific Fund

JPMorgan Japanese Investment Trust

Global Smaller Companies Trust

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.